TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna and Merck reported that adding the personalized mRNA vaccine intismeran to Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda and placebo in a Phase 3 trial. At two years, 82% of patients in the vaccine group were alive without recurrence, compared with 70% in the control group. The companies’ announcement does not provide the full trial data or clarify every detail needed to assess the results.
Moderna and Merck said a Phase 3 trial found their personalized mRNA cancer vaccine, intismeran, reduced the risk of melanoma recurrence or death by 42% when given with Keytruda, compared with Keytruda and placebo. At two years, 82% of patients in the vaccine group were alive without recurrence, versus 70% in the control group, according to the companies’ reported results.
The trial evaluated intismeran, also known as mRNA-4157, as an add-on to pembrolizumab, sold as Keytruda. It involved people with melanoma that had been surgically removed. The comparison group received Keytruda with a placebo. The reported 42% figure refers to a reduction in the risk of recurrence or death relative to that control group; it does not mean that 42% more patients were cured.
At the two-year assessment, recurrence-free survival was 82% among patients receiving intismeran plus Keytruda and 70% among those receiving Keytruda and placebo. Recurrence-free survival measures time without the cancer returning. The companies also reported a 38% reduction in risk of distant metastasis or death with the vaccine combination. At the end of the reported assessment, 88.5% of the combination group were alive without distant metastasis, compared with 80% of the control group.
The results were described in a company announcement covered by Ars Technica. The announcement highlights relative risk reductions and survival estimates, but the information provided does not include the full study report, detailed safety results, or all statistical analyses. Those details are needed to assess the findings alongside the headline figures.
A Personalized Add-On After Surgery
The results suggest that a vaccine tailored to a patient’s tumor could add to the benefit of Keytruda after melanoma surgery, when treatment aims to reduce the chance that cancer returns or spreads. The reported difference in two-year recurrence-free survival was 12 percentage points: 82% compared with 70%. That gives a more direct view of the trial outcome than the relative risk reduction alone.
If the findings are supported by full data and lead to regulatory approval, the approach could offer another post-surgery option for some people with melanoma. But the announcement does not establish that the vaccine is appropriate for every patient, nor does it show that the treatment eliminates the risk of recurrence. Individual benefit, safety, eligibility, and access remain matters for clinical evidence and medical review.
melanoma skin cancer awareness books
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Intismeran Is Tailored
Intismeran is designed using information from an individual patient’s tumor. Researchers compare genetic sequences from cancer cells with those from healthy cells and select cancer-specific mutations. The vaccine uses synthetic mRNA encoding up to 34 selected mutations, with the aim of prompting an immune response directed at features of that patient’s cancer.
The reported trial measured both recurrence-free survival and distant metastasis-free survival. The latter tracks how long patients remain alive without cancer appearing in a different part of the body. The new Phase 3 findings follow a five-year Phase 2 study, which Ars Technica reported showed a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk. The Phase 3 figures reported now are smaller, and results from different studies should not be treated as a direct comparison without fuller data.
“The first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.”
— Dean Li, president of Merck Research Laboratories, in the companies’ announcement
skin cancer self examination guide
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Full Trial Evidence Still Pending
The announcement, as summarized in the available report, does not provide the full study data, including the number of participants, confidence intervals, statistical significance details, or a complete account of adverse events. It is also not clear from the reported figures how long the two-year assessment covered for every participant or when a full peer-reviewed analysis will be available. These details affect how clinicians and researchers can interpret the size and reliability of the reported benefit.
The findings do not establish whether the combination improves overall survival, how well it works across different patient groups, or how its risks compare with those of Keytruda alone. The 42% relative risk reduction should be read alongside the trial’s absolute survival estimates, not as a claim that the vaccine prevents 42% of all recurrences.
UV protection clothing for skin cancer prevention
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Full Results and Regulatory Review
The next steps are the release and review of the complete Phase 3 results, including safety data and the detailed statistical analysis. Regulators would need to assess the evidence before any decision on whether to authorize intismeran for this use. Until then, the reported findings are a company announcement rather than a basis for assuming the vaccine is approved or available as standard treatment.
Further follow-up will also help show whether the separation between the treatment and control groups persists over time. Patients considering melanoma treatment should discuss individual options with their oncology team; the trial announcement alone does not determine which treatment is suitable for a particular person.
Key Questions
What did the trial report about the vaccine?
Moderna and Merck reported that intismeran plus Keytruda reduced the relative risk of melanoma recurrence or death by 42% compared with Keytruda and placebo. At two years, 82% of the vaccine group were alive without recurrence, versus 70% of the control group.
Does a 42% reduction mean 42% of patients were cured?
No. The figure describes a relative reduction in risk compared with the control group. It is not a cure rate or the percentage of patients who avoided recurrence. The reported two-year recurrence-free survival estimates were 82% and 70%.
What is intismeran?
Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed around selected mutations in a patient’s tumor. It was tested alongside pembrolizumab, the immunotherapy drug sold as Keytruda.
Is the vaccine approved for melanoma treatment?
The source material reports trial results announced by the companies, but does not establish that intismeran is approved or available as standard treatment for this use. Regulatory status and access were not specified.
What information is still needed?
The full Phase 3 report is needed to evaluate details such as participant numbers, statistical analyses, follow-up, and side effects. The available account also does not establish whether the combination improves overall survival.
Source: hn
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
